AR037932A1 - Imidazolidinas sustituidas, medicamentos y el uso de dichos compuestos para la preparacion de medicamentos - Google Patents
Imidazolidinas sustituidas, medicamentos y el uso de dichos compuestos para la preparacion de medicamentosInfo
- Publication number
- AR037932A1 AR037932A1 ARP020105018A ARP020105018A AR037932A1 AR 037932 A1 AR037932 A1 AR 037932A1 AR P020105018 A ARP020105018 A AR P020105018A AR P020105018 A ARP020105018 A AR P020105018A AR 037932 A1 AR037932 A1 AR 037932A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon
- unsubstituted
- substituted
- fluorine atoms
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Una imidazolidina de la fórmula (1) en la cual R1 y R2 independientemente uno de otro, son CN, alquilo C1-5, alquenilo C2-5, alquinilo C2-5, cicloalquilo C3-6, o cicloalquenilo C4-6, en los que todas las cadenas de carbono y los anillos de carbono están sin sustituir o están sustituidos, independientemente uno de otro, con 1-11 átomos de flúor o con hasta dos radicales seleccionados del grupo constituido por OH, NH2, NHCH3, N(CH3)2 y OCH3; o R1 y R2 junto con los dos átomos de carbono a los que están unidos, forman un anillo carbonado saturado o insaturado de cinco a ocho miembros, pero sin ningún doble enlace entre los dos átomos de carbono a los cuales R1 y R2 están unidos, y en los que el anillo está sin sustituir o está sustituido con 1-12 átomos de flúor o con hasta dos radicales seleccionados del grupo constituido por CH3 y OCH3; R3 es F, Cl, Br, I, alquilo C1-4, alquenilo C1-4, cicloalquilo C3-6, OH, alcoxi C1-4, O-fenilo, CN, NO2 o NH2; en los que el fenilo está sin sustituir o está sustituido con hasta dos radicales seleccionados del grupo constituido por CH3, F, Cl, Br, I, OH y OCH3; y en los que las cadenas de carbono o los anillo de carbono están sin sustituir o están sustituidos con 1-11 átomos de flúor; R4 a R6 independientemente uno de otro, son H, F ,Cl, Br, I, alquilo C1-4, alquenilo C1-4, cicloalquilo C3-6, OH, alcoxi C1-4, CN, NO2, NH2, alquilamino C1-4, o dialquilamino C1-4; en los que las cadenas de carbono o los anillos de carbono están sin sustituir o están sustituidos con 1-11 átomos de flúor; R7 es H, F, Cl, Br, I, alquilo C1-4, alquenilo C1-4, cicloalquilo C3-6, OH, alcoxi C1-4, CN, NO2 o NH2; en los que las cadenas de carbono o los anillos de carbono están sin sustituir o están sustituidos con 1-11 átomos de flúor; y sus sales farmacéuticamente aceptables, y las sales, del ácido trifluoroacético, medicamentos y el uso de dichos compuestos para la preparación de medicamentos para el tratamiento o profilaxis del sistema nervioso central, del metabolismo de los lípidos, de la infección por ectoparásitos, de trastornos de la función de la vesícula biliar y para mejorar el impulso respiratorio y se usan por tanto para tratar el distrés respiratorio. Adicionalmente , los compuestos aumentan el tono muscular del tracto respiratorio superior, de tal forma que se reduce el ronquido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10163239A DE10163239A1 (de) | 2001-12-21 | 2001-12-21 | Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037932A1 true AR037932A1 (es) | 2004-12-22 |
Family
ID=7710363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020105018A AR037932A1 (es) | 2001-12-21 | 2002-12-19 | Imidazolidinas sustituidas, medicamentos y el uso de dichos compuestos para la preparacion de medicamentos |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1461034B1 (es) |
JP (1) | JP4571803B2 (es) |
KR (1) | KR100959031B1 (es) |
CN (1) | CN100339079C (es) |
AR (1) | AR037932A1 (es) |
AT (1) | ATE345797T1 (es) |
AU (1) | AU2002361990B2 (es) |
BR (1) | BR0215154A (es) |
CA (1) | CA2470856A1 (es) |
CO (1) | CO5590925A2 (es) |
DE (2) | DE10163239A1 (es) |
DK (1) | DK1461034T3 (es) |
ES (1) | ES2275945T3 (es) |
HR (1) | HRP20040573A2 (es) |
HU (1) | HUP0600836A2 (es) |
IL (2) | IL162562A0 (es) |
MA (1) | MA27149A1 (es) |
MX (1) | MXPA04005388A (es) |
MY (1) | MY134344A (es) |
NO (1) | NO20043009L (es) |
PE (1) | PE20030741A1 (es) |
PL (1) | PL368940A1 (es) |
RS (1) | RS53204A (es) |
RU (1) | RU2004122415A (es) |
TW (1) | TW200305408A (es) |
WO (1) | WO2003053434A1 (es) |
ZA (1) | ZA200404149B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10323701A1 (de) | 2003-05-22 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Verfahren zur Synthese heterocyclischer Verbindungen |
WO2005000803A2 (ja) | 2003-06-30 | 2005-01-06 | Sumitomo Chemical Co | 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法 |
DE10341240A1 (de) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
MX2017001117A (es) | 2014-07-25 | 2017-05-08 | Taisho Pharmaceuticals Co Ltd | Compuesto de feniltetrahidroisoquinolina sustituido con heteroarilo. |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236857A (en) * | 1961-10-09 | 1966-02-22 | Boehringer Sohn Ingelheim | 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products |
US3202660A (en) * | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
EP0070084A3 (en) * | 1981-04-24 | 1983-02-16 | Beecham Group Plc | Imidazoline derivatives |
DE3712385A1 (de) * | 1987-04-11 | 1988-10-27 | Boehringer Ingelheim Kg | 2-(phenylimino)imidazolidine |
GB9313330D0 (en) * | 1993-06-28 | 1993-08-11 | Fujisawa Pharmaceutical Co | New compound and its preparation |
EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
DE4328869A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
KR100257129B1 (ko) * | 1993-09-11 | 2000-05-15 | 성재갑 | 신규 세팔로스포린계 항생제 및 이의 제조방법 |
US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
DE19548812A1 (de) * | 1995-12-27 | 1997-07-03 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation |
DE19633966A1 (de) * | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
PT966465E (pt) * | 1997-03-14 | 2003-11-28 | Vertex Pharma | Inibidores do enzima imfdh |
DE19945302A1 (de) * | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19960204A1 (de) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE10015248A1 (de) * | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
DE10019062A1 (de) * | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
DE10060292A1 (de) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
-
2001
- 2001-12-21 DE DE10163239A patent/DE10163239A1/de not_active Withdrawn
-
2002
- 2002-12-09 RS YU53204A patent/RS53204A/sr unknown
- 2002-12-09 CA CA002470856A patent/CA2470856A1/en not_active Abandoned
- 2002-12-09 CN CNB028258177A patent/CN100339079C/zh not_active Expired - Fee Related
- 2002-12-09 IL IL16256202A patent/IL162562A0/xx unknown
- 2002-12-09 AT AT02796586T patent/ATE345797T1/de not_active IP Right Cessation
- 2002-12-09 RU RU2004122415/04A patent/RU2004122415A/ru not_active Application Discontinuation
- 2002-12-09 WO PCT/EP2002/013921 patent/WO2003053434A1/de active IP Right Grant
- 2002-12-09 DE DE50208809T patent/DE50208809D1/de not_active Expired - Lifetime
- 2002-12-09 ES ES02796586T patent/ES2275945T3/es not_active Expired - Lifetime
- 2002-12-09 AU AU2002361990A patent/AU2002361990B2/en not_active Ceased
- 2002-12-09 JP JP2003554191A patent/JP4571803B2/ja not_active Expired - Fee Related
- 2002-12-09 DK DK02796586T patent/DK1461034T3/da active
- 2002-12-09 KR KR1020047009820A patent/KR100959031B1/ko not_active IP Right Cessation
- 2002-12-09 PL PL02368940A patent/PL368940A1/xx not_active Application Discontinuation
- 2002-12-09 BR BR0215154-5A patent/BR0215154A/pt not_active IP Right Cessation
- 2002-12-09 HU HU0600836A patent/HUP0600836A2/hu unknown
- 2002-12-09 MX MXPA04005388A patent/MXPA04005388A/es active IP Right Grant
- 2002-12-09 EP EP02796586A patent/EP1461034B1/de not_active Expired - Lifetime
- 2002-12-11 PE PE2002001194A patent/PE20030741A1/es not_active Application Discontinuation
- 2002-12-19 AR ARP020105018A patent/AR037932A1/es unknown
- 2002-12-19 TW TW091136596A patent/TW200305408A/zh unknown
- 2002-12-20 MY MYPI20024821A patent/MY134344A/en unknown
-
2004
- 2004-05-27 ZA ZA200404149A patent/ZA200404149B/en unknown
- 2004-06-01 MA MA27709A patent/MA27149A1/fr unknown
- 2004-06-16 IL IL162562A patent/IL162562A/en not_active IP Right Cessation
- 2004-06-17 CO CO04056920A patent/CO5590925A2/es not_active Application Discontinuation
- 2004-06-18 HR HR20040573A patent/HRP20040573A2/hr not_active Application Discontinuation
- 2004-07-15 NO NO20043009A patent/NO20043009L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2004122415A (ru) | 2005-03-27 |
EP1461034A1 (de) | 2004-09-29 |
WO2003053434A1 (de) | 2003-07-03 |
KR20040068322A (ko) | 2004-07-30 |
ES2275945T3 (es) | 2007-06-16 |
HRP20040573A2 (en) | 2004-10-31 |
KR100959031B1 (ko) | 2010-05-20 |
AU2002361990B2 (en) | 2008-10-09 |
DK1461034T3 (da) | 2007-03-26 |
AU2002361990A1 (en) | 2003-07-09 |
IL162562A0 (en) | 2005-11-20 |
RS53204A (en) | 2006-10-27 |
BR0215154A (pt) | 2004-10-19 |
NO20043009L (no) | 2004-07-15 |
CN100339079C (zh) | 2007-09-26 |
TW200305408A (en) | 2003-11-01 |
CA2470856A1 (en) | 2003-07-03 |
IL162562A (en) | 2009-12-24 |
MA27149A1 (fr) | 2005-01-03 |
PE20030741A1 (es) | 2003-09-29 |
ZA200404149B (en) | 2006-05-31 |
JP2005516947A (ja) | 2005-06-09 |
JP4571803B2 (ja) | 2010-10-27 |
MY134344A (en) | 2007-12-31 |
MXPA04005388A (es) | 2004-10-11 |
ATE345797T1 (de) | 2006-12-15 |
DE10163239A1 (de) | 2003-07-10 |
HUP0600836A2 (en) | 2008-04-28 |
PL368940A1 (en) | 2005-04-04 |
CO5590925A2 (es) | 2005-12-30 |
CN1606440A (zh) | 2005-04-13 |
DE50208809D1 (de) | 2007-01-04 |
EP1461034B1 (de) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
UY26782A1 (es) | Derivados del benzotiazol | |
ES2164920T3 (es) | Nuevos derivados heterociclicos y uso medicinal de los mismos. | |
ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
AR050260A1 (es) | Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion | |
UY27244A1 (es) | Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple | |
MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
SE0102055D0 (sv) | New Compounds | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
UY28377A1 (es) | Agentes terapeuticos | |
AR032434A1 (es) | Norbornilamino-derivados substituidos, procedimientos para su preparacion, su empleo para la preparcion de medicamentos, asi como el medicamento que los contiene | |
AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
AR037932A1 (es) | Imidazolidinas sustituidas, medicamentos y el uso de dichos compuestos para la preparacion de medicamentos | |
ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
AR042444A1 (es) | Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico | |
AR016212A1 (es) | Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas | |
AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
GT200000087A (es) | Formas polimorfas de un citrato de azabiciclo(2.2.2) octan - 3 - amina y sus composiciones farmaceuticas. | |
SE0301371D0 (sv) | New Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |